A5091303287- Advanced Breast Cancer Therapies
- Cancer Genomics and Diagnostics
- PI3K/AKT/mTOR signaling in cancer
- Single-cell and spatial transcriptomics
- Cancer Cells and Metastasis
- Nanopore and Nanochannel Transport Studies
- Genomics and Chromatin Dynamics
- Pluripotent Stem Cells Research
- Blood groups and transfusion
- Monoclonal and Polyclonal Antibodies Research
- Lipid Membrane Structure and Behavior
- Cancer-related Molecular Pathways
- RNA Research and Splicing
- Genetics and Neurodevelopmental Disorders
- Spectroscopy Techniques in Biomedical and Chemical Research
- HIV Research and Treatment
- Chronic Lymphocytic Leukemia Research
Icahn School of Medicine at Mount Sinai
2018-2020
Memorial Sloan Kettering Cancer Center
2020
Eli Lilly (United States)
2020
Cornell University
2020
University of Central Florida
2013
Seeing double can be a good thing Many human breast cancers harbor activating mutations in PIK3CA , the gene coding for catalytic subunit of phosphoinositide 3-kinase (PI3K). Clinical trials are underway to evaluate efficacy PI3K inhibitors cancer patients. Vasan et al. found unexpectedly that subset not one—but two— mutations, and occur on same allele (see Perspective by Toker). In model systems, hyperactivate signaling enhance tumor growth. Preliminary analysis clinical trial data suggests...
The SIV/macaque model of HIV/AIDS pathogenesis is great importance for understanding the role antibody responses in prevention HIV infection, especially that greater macaque immunoglobulin (IG) gene databases are being developed. We have previously reported construction a phage display library from SIV-infected rhesus (Macaca mulatta) using oligonucleotides primers based on human IG sequences. Our previous screening which relied Sanger sequencing was inefficient and generated only few dozen...
ABSTRACT Genetic and functional complexity of bulk tumor has become evident through rapid advances in sequencing technologies. As a unique integrated approach to characterizing heterogeneity, we demonstrate the multifaceted capabilities novel nanofluidic platform enable single-cell phenotypic genetic profiling ovarian cancer patient-derived cells. This enabled increased resolution cell providing better understanding underlying biological drivers disease. A range CA-125 expression levels is...
Abstract PIK3CA is the most frequently mutated oncogene across all human cancers, and codes for p110α, catalytic subunit of PI3K complex. catalyzes phosphorylation lipid PIP2 to PIP3, which initiates a downstream signaling cascade involving activation AKT mTOR. Hotspot E545K H1047R mutations constitutively activate are oncogenic in multiple cancer histologies including breast cancer, where present 40% tumors target therapy. Recently, PI3Kα inhibitor alpelisib has demonstrated improved PFS...
Abstract Activating mutations in PIK3CA, the gene coding for catalytic subunit (p110α) of phosphoinositide 3-kinase (PI3K), are most frequent oncogenic alterations all cancers, including estrogen receptor-positive (ER+) breast cancer. There many distinct PIK3CA major hotspot (e.g. E542K, E545K, H1047R) which predictive response to PI3Kα inhibitors. While responses inhibitors can be variable, some patients with single mutant tumors derive a deep and prolonged clinical benefit. In...
Activating mutations in PIK3CA, the gene coding for catalytic subunit (p110α) of phosphoinositide 3-kinase (PI3K), are most frequent oncogenic alterations all cancers, including estrogen receptor-positive (ER+) breast cancer. There many distinct PIK3CA major hotspot (e.g. E542K, E545K, H1047R) which predictive response to PI3Kα inhibitors. While responses inhibitors can be variable, some patients with single mutant tumors derive a deep and prolonged clinical benefit. In comprehensive...
Abstract Activating mutations in PIK3CA, the gene coding for catalytic subunit (p110α) of phosphoinositide-3-kinase (PI3K), are most frequent oncogenic alterations estrogen receptor-positive (ER+) breast cancer and also prevalent other tumor types. PI3Kα inhibitors including alpelisib have recently been shown to be clinically active ER+ PIK3CA mutant cancer. To characterize determinants sensitivity these agents, we undertook a comprehensive analysis genomes observed presence double 12-15%...
Abstract The genetic and functional complexity of bulk tumor tissue its associated microenvironment, comprising heterogeneous cellular clones, has become more evident due to rapid advances in single-cell deep-sequencing technologies. In this research, we present methods better characterize clonal diversity from patient-derived cell lines biopsies at the level. We will profile intratumor microenvironmental heterogeneity through selection, DNA RNA sequencing, real-time data. addition data,...
Abstract PIK3CA mutations represent the most frequent oncogenic driver lesion found across all human cancers. Given that single are a predictive biomarker for response to PI3K inhibition, and these clinical benefits small, we hypothesized additional genomic factors may cooperate with in oncogenesis inhibitors. We analyzed several large pan-cancer datasets have discovered phenomenon of dual 15% PIK3CA-mutant cancers, including breast cancer. Dual clonal, both primary untreated metastatic...